Samir Khleif et al. Appl. No. 09/810,310 Amdt. dated May 18, 2005 Reply to Office Action of November 18, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for eliciting an immune response in a subject comprising

administering an immunogenically effective amount of a peptide or protein antigen comprising one or more T cell epitope(s) coordinately with a non-viral vector comprising a polynucleotide encoding at least one of a B7-1, B7-2, and B7-3 co-stimulatory molecule, wherein the non-viral vector and peptide or protein antigen are administered separately to closely adjacent sites.

- 2. (Original) The method of claim 1, wherein the peptide or protein antigen comprises a T cell epitope of a tumor antigen or viral antigen.
 - 3-5. (Canceled)
- 6. (Currently amended) A method for eliciting an immune response in a subject comprising

administering an immunogenically effective amount of a protein antigen comprising at least one T cell epitope coordinately with a non-viral vector comprising a polynucleotide encoding at least one of a B7-1, B7-2, and B7-3 co-stimulatory molecule, wherein the non-viral vector and protein antigen are administered separately to closely adjacent sites.

7. (Original) The method of claim 2, wherein the viral antigen is selected from a human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV) or human papilloma virus (HPV) antigen.

Samir Khleif et al. Appl. No. 09/810,310 Amdt. dated May 18, 2005 Reply to Office Action of November 18, 2004

8. (Original) The method of claim 7, wherein the peptide antigen comprises at least nine contiguous amino acids of a HPV antigenic protein.

9-10. (Canceled)

- 11. (Currently amended) The method of claim 1, wherein the [[B7]] at least one co-stimulatory molecule is B7-1[[,]] or B7-2, B7-3, or B7-H.
- 12. (Currently amended) The method of claim 11, wherein the [[B7]] at least one co-stimulatory molecule is B7-1.
- 13. (Currently amended) The method of claim 1, wherein the peptide antigen and non-viral vector encoding one or more B7 co-stimulatory molecules are administered to the subject simultaneously as a mixture in a pharmaceutically acceptable carrier or diluent.
- 14. (Currently amended) The method of claim 1, wherein the peptide antigen and non-viral vector encoding the B7 co-stimulatory molecule are administered separately to the subject in a sequential vaccination protocol.
- 15. (Currently amended) The method of claim 1, wherein the peptide antigen and non-viral vector encoding the B7 co stimulatory molecule are administered to proximal target sites selected from the same, or closely-adjacent, intradermal, subcutaneous, mucosal or intratumoral sites.
- 16. (Original) The method of claim 1, wherein the non-viral vector is selected from a RNA or DNA vector.
- 17. (Currently amended) The method of claim 1, wherein the non-viral vector comprises a naked DNA vector having the polynucleotide encoding the co-stimulatory molecule(s) operably linked to regulatory elements necessary for expression of the co-stimulatory molecule(s) in eukaryotic cells.

PATENT

Samir Khleif et al.
Appl. No. 09/810,310
Amdt. dated May 18, 2005
Reply to Office Action of November 18, 2004

18-31. (Canceled)